Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

30.140
+2.1607.72%
Volume:9.34M
Turnover:277.40M
Market Cap:10.67B
PE:-33.87
High:30.480
Open:28.020
Low:28.020
Close:27.980
52wk High:58.600
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:2.31
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:1.75
PE(LYR):-33.87
PS:3.79

Loading ...

Everest Medicines Ltd - Mr. Wei Fu Purchases 660,000 Shares for HK$20.7 Mln at HK$31.25 per Share on May 14

THOMSON REUTERS
·
May 15

EVEREST MED Shares Climb Over 3% Following Release of Initial Human Data for mRNA Cancer Vaccine EVM16

Stock News
·
May 14

Everest Medicines says Milestone consent condition met for asset purchase agreement

Reuters
·
Apr 27

Everest Medicines Issues April 2026 Reminder on Electronic Dissemination of Corporate Communications

Bulletin Express
·
Apr 23

Everest Medicines publishes 2025 environmental, social and governance report

Reuters
·
Apr 23

Everest Medicines publishes 2025 annual report

Reuters
·
Apr 23

Everest MED Shares Climb Over 4% in Morning Session on AACR Data Release

Stock News
·
Apr 21

EVEREST MED Adds 3,250 Shares in March; New 2026 Equity Scheme Opens 35.36 Million-Share Mandate

Bulletin Express
·
Apr 09

BRIEF-Everest Medicines Says Aggregate Consideration Under Share Purchase Agreement Is $250 Million

Reuters
·
Apr 08

EVEREST MED Forges Acquisition Pact with Hisun Biopharm to Broaden Asia-Pacific Commercial Footprint

Stock News
·
Apr 08

Everest Med Plans US$250 Million Acquisition of Hasten’s Singapore Unit to Broaden APAC Chronic-Disease Portfolio

Bulletin Express
·
Apr 08

Everest Medicines signs deal to buy Hasten Biopharmaceuticals SG for US$250 million

Reuters
·
Apr 08

Everest Medicines - Unit to Buy Entire Equity Interest in Hasten Biopharmaceuticals (SG) Pte

THOMSON REUTERS
·
Apr 08

Everest Medicines - Aggregate Consideration Under Share Purchase Agreement Is US$250 Mln

THOMSON REUTERS
·
Apr 08